pocketful logo
Lincoln Pharmaceuticals Ltd logo

Lincoln Pharmaceuticals Ltd

NSE: LINCOLN BSE: 531633

654.30

(6.25%)

Sat, 14 Feb 2026, 03:16 am

Lincoln Pharmaceuticals Share Price Live Chart

1 Day

0 (0%)

No Result Found

Summary

  • Market Cap

    1297.13

  • Net Profit

    82.35

  • P/B

    1.64

  • Sector P/E

    32.04

  • P/E

    13.42

  • EV/EBITDA

    8.73

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    12.78

  • ROCE (Industry)

    15.36

  • RONW (Industry)

    13.46

  • ROE

    13.02

  • ROCE

    17.42

  • Debt/Equity

    0

  • EPS (TTM)

    43.85

  • Dividend Yield

    0.28

  • Book Value

    357.35

  • Interest Cover

    59.08

Analysis

all

thumbs up icon

Pros

  • Dividends per share have increased over the past 10 years.
  • Dividends paid are thoroughly covered by earnings (17x coverage).
  • Lincoln Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Lincoln Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Lincoln Pharmaceuticals's earnings are expected to exceed the low risk growth rate next year.
thumbs up icon

Cons

  • Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
  • Lincoln Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
  • Lincoln Pharmaceuticals's earnings are expected to grow by 15.9% yearly, however this is not considered high growth (20% yearly).
  • Lincoln Pharmaceuticals's earnings growth is positive but not above the India market average.
  • Lincoln Pharmaceuticals's revenue is expected to grow by 13.2% yearly, however this is not considered high growth (20% yearly).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersDEC 2025SEPT 2025JUN 2025MAR 2025DEC 2024
Promoters49.7849.7849.7849.7849.78
FII4.704.725.145.005.16
DII0.010.010.010.010.00
Public45.5245.4945.0745.2245.06
Government00000

Read More

Technical Analysis

RSI

83.55

MACD

27.35

50 DMA

484.18

200 DMA

532.65

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic597.15532.15494.30467.15429.30402.15337.15
Fibonacci532.15507.32491.98467.15442.32426.98402.15
Camarilla474.32468.37462.41467.15450.49444.53438.57

Pivots Level: Classic

R3

+130.00

597.15

R2

+65.00

532.15

R1

+27.15

494.30

467.15
467.15
Pivot Point
LTP: 654.30

S1

-37.85

429.30

S2

-65

402.15

S3

-130

337.15

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    538.23

  • 20-EMA

    508.34

  • 30-EMA

    498.90

  • 50-EMA

    495.89

  • 100-EMA

    506.35

  • 200-EMA

    533.58

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
12 Feb 2026board-meetingsQuarterly Results
13 Nov 2025board-meetingsQuarterly Results, Half Yearly Results
29 Aug 2025agm
22 May 2025dividend₹1.80 Dividend /Share12 Sept 2025
02 Sept 2024agm
16 May 2024dividend₹1.80 Dividend /Share14 Sept 2024
26 Aug 2023agm
25 May 2023dividend₹1.50 Dividend /Share16 Sept 2023
26 Aug 2022agm
19 May 2022dividend₹1.50 Dividend /Share17 Sept 2022

Read More

Peer Comparison

Lincoln Pharmaceuticals Ltd logo

Lincoln Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Cipla Ltd logo

Cipla Ltd

Read More

Lincoln Pharmaceuticals Ltd About

Lincoln Pharmaceuticals is engaged in the business of manufacturing and trading of pharmaceutical products.

Industry

Pharmaceuticals - Indian - Formulations

Founded

1995

Headquarters

CEO

Kishorbhai M Shah

Employees

Contact

Website icon

Website

http://www.lincolnpharma.com

Email icon

Email

cs@lincolnpharma.com; investor@lincolnpharma.com

Phone icon

Phone

91-079-67778000

Location icon

Location

Lincoln House B/H Satyam Compe, Science City Road Sola, Ahmedabad, Gujarat, 380060

Read More

Lincoln Pharmaceuticals Ltd Company History

YearHistory
2014
  • Lincoln Pharmaceuticals Ltd has launched an Ultramodern State of Art plant for Injectable.
  • Company has commended the payment of Dividend of Rs. 0.60/- per equity share (@ 6%) of face value of Rs. 10/- each of the Company.
2015
  • The company has successfully launched a cough syrup called Namcold DX which contains Dextromethorphan Polistrirex.
2016
  • Lincoln Pharmaceuticals launches Vaginal Spray for FIRST TIME IN INDIA.
2020
  • Lincoln Pharma gets Gujarat food & drug regulator nod to manufacture COVID-19 drugs.
  • The company has received approval from the state regulator to manufacture varied dosages of HCQ tablets and HCQ sulfate tablets among others at Khatraj plant.
2021
  • The company received approval for the company's manufacturing facility from Australia's medicines and medical devices regulator.

Read More

Deals

Client NameOrder SideQTYAvg PriceDate
GREENX WEALTH MULTIHORIZONS OPPORTUNITY FUNDBuy165255603.0712 Feb 2026
IRAGE BROKING SERVICES LLPSell125529602.2507 Aug 2025
IRAGE BROKING SERVICES LLPBuy92372599.3507 Aug 2025
MUSIGMA SECURITIESBuy160300604.9707 Aug 2025
NK SECURITIES RESEARCH PRIVATE LIMITEDSell275585600.3907 Aug 2025
MUSIGMA SECURITIESSell160300606.0407 Aug 2025
IRAGE BROKING SERVICES LLPBuy137847600.7407 Aug 2025
IRAGE BROKING SERVICES LLPSell104690598.8707 Aug 2025
NK SECURITIES RESEARCH PRIVATE LIMITEDBuy275585599.4907 Aug 2025
HITESH BABUBHAI MANGUKIYABuy139797923.3905 Dec 2024

Read More

Lincoln Pharmaceuticals Ltd News

Lincoln Pharma Q3FY26 Net Profit Surges 37.70% YoY

Lincoln Pharmaceuticals reports consolidated net profit of ₹28.60 crore in Q3FY26, up 37.70% YoY. Revenue from operations grows 13.49% to ₹166.32 crore with strong performance across therapeutic segments.

12 Feb 2026

co actions results

Lincoln Pharmaceuticals Gets CRISIL A/Stable Rating

Lincoln Pharmaceuticals receives credit rating reaffirmation from CRISIL with long-term facilities at CRISIL A/Stable and short-term at CRISIL A1, reflecting strong financial profile.

10 Jan 2026

stocks

Lincoln Pharmaceuticals Reports 24% Drop in Q2 Net Profit Despite Revenue Stability

Lincoln Pharmaceuticals reported a consolidated net profit of Rs. 20.01 crore for Q2FY26, down 24.06% year-on-year, while total income remained stable at Rs. 170.60 crore with only a 0.34% decline. The company targets Rs. 1,000 crore revenue within three years and aims for 15-18% annual growth, driven by expansion in cardiac, diabetic, dermatology, and ENT segments.

13 Nov 2025

earnings

Lincoln Pharma Reports 17% Net Profit Growth in Q1 Results

Lincoln Pharmaceuticals reported net profit of Rs 27.70 crore for the April-June quarter, marking a 17% increase from Rs 23.69 crore in the same period last year. Total income grew 7.3% to Rs 169.34 crore compared to Rs 157.69 crore in the previous year. EBITDA rose 17.92% to Rs 39.08 crore from Rs 33.14 crore year-on-year. The company targets Rs 1,000 crore revenue within three years through business expansion into high-value product lines and new markets, aiming for 15-18% annual growth driven by cardiac, diabetic, dermatology, and ENT segments. During the quarter, the company launched its bulk drug manufacturing plant with Rs 4 crore investment from internal funds and received approvals for 10 products. Company shares surged 8.47% to close at Rs 576.90 on BSE.

07 Aug 2025

earnings

Lincoln Pharmaceuticals Re-appoints Four Key Directors for Five-Year Terms

Lincoln Pharmaceuticals Limited's Board of Directors approved the re-appointment of four senior executives for five-year terms, subject to shareholder approval at the upcoming Annual General Meeting. Mahendra G. Patel was re-appointed as Managing Director from October 1, 2025 to September 30, 2030. Three Whole Time Directors were also re-appointed: Hashmukh I. Patel for the same October 2025 to September 2030 period, while Ashish R. Patel and Munjal M. Patel will serve from November 14, 2025 to November 13, 2030. The appointments were recommended by the Nomination and Remuneration Committee. Mahendra G. Patel, a law graduate with over 45 years of pharmaceutical industry experience, has served as Managing Director since the company's incorporation and is a company promoter. Hashmukh I. Patel, a science graduate with three decades of pharma experience, manages domestic marketing and sales distribution. Ashish R. Patel holds an MBA in Marketing from the UK and handles marketing operations and sales strategies. Munjal M. Patel has a Master's degree in Finance from the USA with over 10 years of pharma experience and manages international trade and financial matters.

07 Aug 2025

corporate governance

Read More

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

pocketful logo

2022-25 Pocketful. All rights reserved, Built with in India

Version -5.76

app image 1app image 2

Explore

Calculatorsfooter arrow down icon
Popular Calculatorsfooter arrow down icon
Group Stocksfooter arrow down icon

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800